Stocks Health care BDPT
OTC · Health careBioadaptives, Inc. (BDPT)
Bioadaptives, Inc. brought in $25.6K of revenue over the twelve months to June 30, 2026, up 694.1% from a year earlier. It posted a net loss of $1.2M. In fiscal 2025 capital spending exceeded operating cash flow by $534K. At June 30, 2026 it held $29.2K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 19, 2026.
Watch BDPT in 60 secondsWhat Bioadaptives, Inc. does
Bioadaptives, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker BDPT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $18.3K | -$1.6M | -$0.15 | -$534K |
| 2024 | $12.7K | -$899.2K | -$0.11 | -$249.5K |
| 2023 | $28.6K | -$712.5K | -$0.12 | n/a |
| 2022 | $17.2K | -$895.6K | n/a | n/a |
| 2021 | $19.8K | -$1M | n/a | n/a |
| 2020 | $16.3K | -$847.2K | -$0.04 | n/a |
Full financial statements: income, balance sheet and cash flow
Where BDPT ranks in Health care
Latest SEC filings
What Bioadaptives, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 19, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 55% to $5K versus the same quarter last year; diluted EPS $0.00 versus -$0.02.
- August 14, 2026Late quarterly report notice NT 10-Q
- May 15, 2026Quarterly report 10-Q · period to March 31, 2026Revenue was $5.5K; diluted EPS -$0.01 versus -$0.02.
- April 14, 2026Annual report 10-K · period to December 31, 2025Revenue rose 44% to $18.3K versus the prior year; diluted EPS -$0.15 versus -$0.11.
- March 31, 2026Late annual report notice NT 10-K
- November 14, 2025Quarterly report 10-Q · period to September 30, 2025Revenue was $4.6K; diluted EPS -$0.04 versus $0.00.
- August 14, 2025
- May 13, 2025
- April 15, 2025Annual report 10-K · period to December 31, 2024Revenue fell 56% to $12.7K versus the prior year; diluted EPS -$0.11 versus -$0.12.
- March 31, 2025Late annual report notice NT 10-K
Insider trades
What the people running Bioadaptives, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Questions about BDPT
What does Bioadaptives, Inc. do?
Bioadaptives, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker BDPT.
Is Bioadaptives, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $1.2M on revenue of $25.6K.
How much revenue does Bioadaptives, Inc. make?
Over the twelve months to June 30, 2026 Bioadaptives, Inc. reported revenue of $25.6K. That is 694.1% more than a year earlier.
When did Bioadaptives, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 19, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 3, 2026.
Similar companies
Compare BDPT with
Follow BDPT
Get an email when Bioadaptives, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow BDPT: get an email when it filesWhere the numbers come from
Financial figures are the values Bioadaptives, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.